Leukemia, Myelomonocytic, Chronic
"Leukemia, Myelomonocytic, Chronic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A myelodysplastic-myeloproliferative disease characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.
| Descriptor ID |
D015477
|
| MeSH Number(s) |
C04.557.337.539.522 C15.378.190.615.510
|
| Concept/Terms |
Leukemia, Myelomonocytic, Chronic- Leukemia, Myelomonocytic, Chronic
- Myelomonocytic Leukemia, Chronic
- Chronic Myelomonocytic Leukemia
- Chronic Myelomonocytic Leukemias
- Leukemia, Chronic Myelomonocytic
- Leukemias, Chronic Myelomonocytic
- Myelomonocytic Leukemias, Chronic
|
Below are MeSH descriptors whose meaning is more general than "Leukemia, Myelomonocytic, Chronic".
Below are MeSH descriptors whose meaning is more specific than "Leukemia, Myelomonocytic, Chronic".
This graph shows the total number of publications written about "Leukemia, Myelomonocytic, Chronic" by people in this website by year, and whether "Leukemia, Myelomonocytic, Chronic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 1998 | 4 | 0 | 4 |
| 1999 | 2 | 0 | 2 |
| 2000 | 1 | 0 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 1 | 2 | 3 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 4 | 1 | 5 |
| 2007 | 3 | 1 | 4 |
| 2008 | 2 | 1 | 3 |
| 2009 | 2 | 0 | 2 |
| 2010 | 2 | 1 | 3 |
| 2011 | 1 | 0 | 1 |
| 2012 | 2 | 0 | 2 |
| 2013 | 3 | 0 | 3 |
| 2014 | 5 | 1 | 6 |
| 2015 | 5 | 0 | 5 |
| 2016 | 3 | 0 | 3 |
| 2017 | 9 | 3 | 12 |
| 2018 | 11 | 0 | 11 |
| 2019 | 0 | 1 | 1 |
| 2020 | 6 | 0 | 6 |
| 2021 | 4 | 0 | 4 |
| 2022 | 7 | 1 | 8 |
| 2023 | 7 | 0 | 7 |
| 2024 | 6 | 1 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leukemia, Myelomonocytic, Chronic" by people in Profiles.
-
Integrated Clinical Genotype-Phenotype Characteristics of STAT3-Mutated Myeloid Neoplasms. Clin Cancer Res. 2024 Oct 15; 30(20):4681-4689.
-
ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia. Haematologica. 2024 Oct 01; 109(10):3419-3425.
-
Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm. Blood Adv. 2024 06 11; 8(11):2695-2706.
-
Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia. Cell Rep Med. 2024 Jun 18; 5(6):101585.
-
Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia. Leukemia. 2024 May; 38(5):1178-1181.
-
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol. 2024 Mar; 11(3):e186-e195.
-
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol. 2024 Jan; 11(1):e15-e26.
-
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. Am J Hematol. 2024 02; 99(2):E32-E36.
-
Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. Br J Haematol. 2024 Mar; 204(3):898-909.
-
A case of sudden hearing loss in a patient with chronic myelomonocytic leukemia. Ann Hematol. 2023 Dec; 102(12):3427-3430.